{"id":67803,"date":"2014-08-09T02:00:46","date_gmt":"2014-08-09T06:00:46","guid":{"rendered":"http:\/\/www.eugenesis.com\/dgap-news-magforce-ag-successful-final-closing-of-a-growth-financing-round-for-magforce-usa-inc-under-the-lead-of\/"},"modified":"2014-08-09T02:00:46","modified_gmt":"2014-08-09T06:00:46","slug":"dgap-news-magforce-ag-successful-final-closing-of-a-growth-financing-round-for-magforce-usa-inc-under-the-lead-of","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanomedicine-2\/dgap-news-magforce-ag-successful-final-closing-of-a-growth-financing-round-for-magforce-usa-inc-under-the-lead-of.php","title":{"rendered":"DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of &#8230;"},"content":{"rendered":"<p><p>    DGAP-News: MagForce AG \/ Key word(s): Private Equity  MagForce AG: Successful final closing of a growth financing round  for  MagForce USA, Inc. under the lead of Mithril Capital Management<\/p>\n<p>    08.08.2014 \/ 14:00  <\/p>\n<p>    ---------------------------------------------------------------------  <\/p>\n<p>    MagForce AG: Successful final closing of a growth financing    round for    MagForce USA, Inc. under the lead of Mithril Capital Management  <\/p>\n<p>    Berlin, Germany, August 8th, 2014 - MagForce AG (Frankfurt,    Entry Standard,    XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device    company in the    field of nanomedicine focused on oncology, today announced that    its    subsidiary MagForce USA, Inc. has successfully closed its    growth financing    round. Mithril Capital Management, a growth-stage technology    fund founded    by Ajay Royan and Peter Thiel, led a group of strategic    investors including    the management in financing MagForce USA's growth round with    proceeds of    USD 15 million, with an option to increase the size of the    round to USD 30    million. MagForce AG owns 77% of MagForce USA as of this    closing. The    strategic investors presently hold 23% of MagForce USA and may    increase    their ownership in future by exercising the warrants held by    them. After    all warrants are exercised, MagForce AG will continue to retain    a majority    ownership position in MagForce USA.  <\/p>\n<p>    MagForce USA, Inc., has been granted a license by MagForce AG    for the    development and commercialization of NanoTherm(TM) Therapy for    the    treatment of brain and prostate cancers and will be responsible    for    developing the North American market (US, Mexico and Canada)    for MagForce's    technology and products. Under the prostate cancer license,    MagForce USA    will also receive royalties for the sale of NanoTherm(TM)    particles for the    treatment of prostate cancer outside North America.  <\/p>\n<p>    Ben J. Lipps, Chairman and CEO of MagForce AG and also of    MagForce USA,    Inc., commented: \"I am very optimistic about the US market,    which has the    largest potential especially for prostate cancer treatment.    MagForce USA    aims at developing its technology to offer a new focal    treatment for    Intermediate Stage Prostate Cancer with precise ablation of the    cancer    lesion while sparing normal tissue. In Mithril, we have found    the right    collaborator to support our expansion plans. Ajay Royan and    Peter Thiel    have proven themselves numerous times to be valuable partners    in helping    companies unlock long-term growth.\"  <\/p>\n<p>    Ajay Royan, co-founder and managing general partner of Mithril,    said:    \"Conventional treatments for prostate cancer have significant    side effects    and other limitations, while patients with glioblastoma    currently have few    good options at all. That's why MagForce's innovative approach    to solid    tumors is very promising and potientially important.\"  <\/p>\n<p>    About MagForce AG and MagForce USA, Inc.    MagForce AG, listed in the entry standard of the Frankfurt    Stock Exchange    (MF6, ISIN: DE000A0HGQF5), together with its subsidiary    MagForce USA, Inc.    is a leading medical device company in the field of    nanomedicine focused on    oncology. The Group's proprietary NanoTherm(TM) therapy enables    the    targeted treatment of solid tumors through the intratumoral    generation of    heat via activation of superparamagnetic nanoparticles.    NanoTherm(TM),    NanoPlan(R), and NanoActivator(R) are components of the therapy    and have    received EU-wide regulatory approval as medical devices for the    treatment    of brain tumors. MagForce, NanoTherm, NanoPlan, and    NanoActivator are    trademarks of MagForce AG in selected countries. For more    information,    please visit: <a href=\"http:\/\/www.magforce.com\" rel=\"nofollow\">http:\/\/www.magforce.com<\/a>.    Please learn more: video (You Tube)  <\/p>\n<p>    About Mithril Capital Management    Mithril is a global investment firm that provides capital to    leading growth    companies by partnering with teams who use technology to    build    transformative and durable businesses, often in industries long    overdue for    change. Each of these businesses is unique, but all face common    challenges    to unlocking long-term growth. Mithril helps navigate these    critical    inflection points by investing in size and with conviction. For    more    information, please visit: <a href=\"http:\/\/www.mithril.com\" rel=\"nofollow\">http:\/\/www.mithril.com<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View original post here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.wallstreet-online.de\/nachricht\/6919126-dgap-news-magforce-ag-successful-final-closing-of-a-growth-financing-round-for-magforce-usa-inc-under-the-lead-of-mithril-capital-management\/RK=0\/RS=hyjftWJgKG8oGZi1LnHt_h401Dg-\" title=\"DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of ...\">DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> DGAP-News: MagForce AG \/ Key word(s): Private Equity MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of Mithril Capital Management 08.08.2014 \/ 14:00 --------------------------------------------------------------------- MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanomedicine-2\/dgap-news-magforce-ag-successful-final-closing-of-a-growth-financing-round-for-magforce-usa-inc-under-the-lead-of.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577779],"tags":[],"class_list":["post-67803","post","type-post","status-publish","format-standard","hentry","category-nanomedicine-2"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/67803"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=67803"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/67803\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=67803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=67803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=67803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}